A pilot randomized controlled trial of liraglutide 3.0 mg for binge eating disorder

Abstract Objective To assess the efficacy of liraglutide 3.0 mg, a glucagon‐like peptide‐1 (GLP‐1) receptor agonist, for binge eating disorder (BED). Methods Adults with a body mass index (BMI) ≥ 27 kg/m2 enrolled in a pilot, 17‐week double‐blind, randomized controlled trial of liraglutide 3.0 mg/da...

Popoln opis

Bibliografske podrobnosti

Principais autores:	Kelly C. Allison, Ariana M. Chao, Maija B. Bruzas, Courtney McCuen‐Wurst, Elizabeth Jones, Cooper McAllister, Kathryn Gruber, Robert I. Berkowitz, Thomas A. Wadden, Jena S. Tronieri
Format:	Artigo
Jezik:	Inglês
Izdano:	Wiley 2023-04-01
Serija:	Obesity Science & Practice
Teme:	binge eating disorder binge episodes eating disorder liraglutide loss of control eating weight loss medication
Online dostop:	https://doi.org/10.1002/osp4.619
Oznake:	Označite Brez oznak, prvi označite!